ANIK

Anika Therapeutics Inc

Add to Watchlist

Advanced Chart

8.730

-0.35(-3.855%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

8.965

Open

8.965

VWAP

8.77

Vol

40.03K

Mkt Cap

130.92M

Low

8.630

Amount

350.92K

EV/EBITDA(TTM)

3.90

Total Shares

14.83M

77.75M

EV/OCF(TTM)

12.38

P/S(TTM)

1.15

Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.

Trade Smarter with Intellectia.AI

300K+ trust us for AI trading signals that capture market momentum early!

Trade Smarter with Intellectia.AI

300K+ trust us for AI trading signals that capture market momentum early!

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

27.91M

+6.64%

-0.040

-33.33%

29.07M

-5.02%

0.030

-200%

27.53M

-28.95%

0.020

-108%

Estimates Revision

The market is revising Upward the revenue expectations for Anika Therapeutics, Inc. (ANIK) for FY2025, with the revenue forecasts being adjusted by 0.95% over the past three months. During the same period, the stock price has changed by -22.88%.

Revenue Estimates for FY2025

Revise Upward

+0.95%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-22.22%

In Past 3 Month

Stock Price

Go Down

-22.88%

In Past 3 Month

3 Analyst Rating

109.97% Upside

Wall Street analysts forecast ANIK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIK is 18.33 USD with a low forecast of 15.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

109.97% Upside

Current: 8.730

Low

15.00

Averages

18.33

High

24.00

109.97% Upside

Current: 8.730

Low

15.00

Averages

18.33

High

24.00

Barrington

Outperform

maintain

$20 -> $19

2025-05-12

Reason

Barrington

Price Target

$20 -> $19

2025-05-12

maintain

Outperform

Reason

Barrington lowered the firm's price target on Anika Therapeutics to $19 from $20 and keeps an Outperform rating on the shares. While the Q1 miss is "frustrating," Anika's product pipeline holds material value that will "begin to be unlocked in a significant way" over the next two years, the analyst tells investors in a research note. The firm thinks the recent share price weakness "provides a very good entry point for new investors and is a great opportunity to add to positions for long-suffering, current investors."

Barrington Research

Michael Petusky

Buy

Maintains

$25 → $20

2025-03-13

Reason

Barrington Research

Michael Petusky

Price Target

$25 → $20

2025-03-13

Maintains

Buy

Reason

Barrington lowered the firm's price target on Anika Therapeutics to $20 from $25 and keeps an Outperform rating on the shares. Anika management reduced its previous adjusted EBITDA guidance for FY25, which had previously been forecast to be a double-digit margin but is now expected to be 8-10%, with pricing weakness in osteoarthritis pain management in the U.S. appearing to be the primary reason for the lowered outlook, the analyst tells investors.

Barrington Research

Michael Petusky

Buy

Maintains

$37 → $25

2024-11-01

Reason

Barrington Research

Michael Petusky

Price Target

$37 → $25

2024-11-01

Maintains

Buy

Reason

Barrington analyst Michael Petusky lowered the firm's price target on Anika Therapeutics to $25 from $37 and keeps an Outperform rating on the shares after Q3 results fell short of expectations and the company "materially reduced" its previous adjusted EBITDA guidance for FY24. Weakening OA pain volumes and softer pricing in the U.S. were the primary factors in "the more pessimistic outlook," notes the analyst, who notes the firm's target is based on its FY25 adjusted EBITDA estimate plus $50M of value it adds for the company's "two potential needle-mover products," namely Cingal and Hyalofast, that have completed pivotal trials but have not yet received U.S. approval.

Barrington Research

Michael Petusky

Buy

Maintains

$37

2024-10-22

Reason

Barrington Research

Michael Petusky

Price Target

$37

2024-10-22

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Anika Therapeutics Inc (ANIK.O) is 218.00, compared to its 5-year average forward P/E of 202.35. For a more detailed relative valuation and DCF analysis to assess Anika Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

202.35

Current PE

218.00

Overvalued PE

856.95

Undervalued PE

-452.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-61.56

Current EV/EBITDA

24.28

Overvalued EV/EBITDA

361.29

Undervalued EV/EBITDA

-484.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

2.63

Current PS

1.04

Overvalued PS

3.47

Undervalued PS

1.80

Intellectia.AI: Your Edge in Stock Trading

Join 300K+ users and access AI-powered stock picks that spot trends in minutes!

Intellectia.AI: Your Edge in Stock Trading

Join 300K+ users and access AI-powered stock picks that spot trends in minutes!

Financials

Annual

Quarterly

FY2025Q2

YoY :

-8.15%

28.22M

Total Revenue

FY2025Q2

YoY :

+1749.56%

-4.18M

Operating Profit

FY2025Q2

YoY :

+82.88%

-4.65M

Net Income after Tax

FY2025Q2

YoY :

+2700.00%

-0.28

EPS - Diluted

FY2025Q2

YoY :

-62.97%

-1.66M

Free Cash Flow

FY2025Q2

YoY :

-23.68%

50.90

Gross Profit Margin - %

FY2025Q2

YoY :

-185.34%

-0.99

FCF Margin - %

FY2025Q2

YoY :

+99.15%

-16.47

Net Margin - %

FY2025Q2

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

102.7K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Unlock Winning Stocks with Intellectia.AI

Trusted by 300K+ investors. Get AI-driven trading signals to seize opportunities fast!

Unlock Winning Stocks with Intellectia.AI

Trusted by 300K+ investors. Get AI-driven trading signals to seize opportunities fast!

ANIK News & Events

Events Timeline

2025-07-30 (ET)

2025-07-30

07:13:01

Anika updates its 2026-2027 revenue guidance for potential Hyalofast delay

2025-07-30

07:12:19

Anika Therapeutics reaffirms FY25 adjusted EBITDA view of down 3% to up 3%

2025-07-30

07:10:45

Anika Therapeutics reports Q2 adjusted EPS (13c) vs 4c last year

News

7.0

08-13Globenewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK

7.0

08-12Globenewswire

ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. Continues Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm

7.0

08-09Globenewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anika Therapeutics, Inc. - ANIK